Matt Karlyn
Matt Karlyn has 25 years of experience in working with companies in the healthcare, pharmaceutical, medical device, and technology industries on a wide range of commercial life sciences, licensing, and technology transactions. His clients range from Fortune 100 companies to start-ups, and he regularly advises companies on matters involving IP commercialization, complex collaboration transactions, licensing initiatives, subscription-based economics, and business transactions related to the procurement, development, commercialization, and use of technology and life sciences products. He has also worked with a number of clients on corporate transactions including mergers and acquisitions, as well as private equity and venture capital financing.
Matt is ranked Band 1 by Chambers USA for Intellectual Property: Licensing in Massachusetts. Clients in Chambers describe Matt as: “accessible and engaged, and he is really focused on getting the right answer for us."
Life Sciences
Life sciences clients, including pharmaceutical, medical device, and healthcare companies, rely on Matt for his breadth of knowledge in licensing, collaboration, and commercialization strategies across a wide range of transactions designed to strengthen operations and maximize value. Matt’s clients come from sectors across the global economy and include emerging companies, privately held companies, and many of the world’s biggest brands.
Matt has broad experience with commercial transactions and agreements in the life sciences space, including:
- Intellectual property and technology licenses
- Collaboration and development transactions
- Commercialization agreements
- Supply and manufacturing transactions
Technology
Matt regularly advises on the use of technology in business, pricing strategies, and market terms across a wide variety of technology transactions that benefit clients both large and small. He has extensive experience negotiating a wide range of transactions, including:
- Enterprise resource planning and customer relationship management licensing and implementation transactions
- Cloud-based transactions including software-as-a-services, platform-as-a-service, and infrastructure-as-a-service.
- Software licensing
- Supply chain and procurement deals
Additionally, Matt has worked on many of the largest outsourcing transactions in the United States, representing numerous Fortune 100 companies on information technology, business process, finance and accounting, facilities services, and other outsourcing transactions.
Matt is a frequent author and speaker on topics pertaining to drafting and negotiating commercial technology, outsourcing, and licensing transactions. He has published over 25 articles (including chapters in two books), given over 175 presentations on licensing, technology, outsourcing, and data security, and is the co-author of A Guide to IT Contracting: Checklists, Tools, and Techniques.
Matt is currently co-chair of the Legal and Regulatory policy group at the Massachusetts Biotechnology Council. He served as chair of the New England Chapter of the International Association of Outsourcing Professionals, and served for five years on the board of directors of Julie’s Family Learning Program, a wellness program for mothers and children in South Boston. Matt has also been elected as a Fellow of the American Bar Foundation.
Experience
CSPC Pharmaceutical Group Limited
USD 1.5 billion+ exclusive license agreement between CSPC Pharmaceutical Group Limited and Elevation Oncology, Inc. to supply, develop and commercialize SYSA1801, a clinical stage antibody drug conjugate (ADC) targeting Claudin18.2, in all global territories outside Greater China.
CSPC Pharmaceutical Group Limited
USD 700 million+ exclusive license agreement between CSPC Pharmaceutical Group Limited and Corbus Pharmaceutical Holdings to supply, develop and commercialize SYS6002, a clinical stage antibody drug conjugate (ADC) targeting Nectin-4, in the U.S., Australia, Canada, and varied European countries.
ACEA Therapeutics
Represented ACEA Therapeutics in an exclusive license agreement with Sorrento Therapeutics to develop and commercialize Abivertinib, a novel small molecule tyrosine kinase inhibitor (TKI) that selectively targets both mutant forms of the epidermal growth factor receptor (EGFR) and Bruton’s tyrosine kinase (BTK).
ACEA Therapeutics
Represented ACEA Therapeutics in USD 488 million merger and acquisition transaction by their licensee, Sorrento Therapeutics.
Kindred Biosciences
Represented Kindred Biosciences in an exclusive license agreement with Elanco Animal Health Incorporated to globally develop and commercializeKIND-030, a monoclonal antibody targeting canine parvovirus (CPV).
Kindred Biosciences
Represented Kindred Biosciences, Inc. in USD 440 million acquisition transaction by their licensee, Elanco US, Inc.
Sanuwave Health
Represented Sanuwave Health in a license and marketing agreement with Celularity Inc. to commercialize BIOVANCE® Human Amniotic Membrane Allograft and Interfyl® Human Connective Tissue Matrix.
MyChem
Represented MyChem, a privately held provider of proprietary, ultra-pure nucleotides to customers in the diagnostics, pharma, genomics and research markets, in connection with its ≈ USD 240 million sale to Maravai (NASDAQ: MRVI).
Special New Fruist Licensing (SNFL)
Represented Special New Fruit Licensing (SNFL) in its acquisition of International Fruit Genetics (IFG).
Sequlite Genomics
Represented Sequlite Genomics, a company that focuses on developing Next-Generation Sequencing (NGS) technology, in connection with its sale to Fapon Biotech.
Arbutus Biopharma
Represented Arbutus Biopharma in its Clinical Collaboration Agreement with Assembly Biosciences to evaluate the combination of core inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in patients with chronic Hepatitis B virus infection.
OpenInvest
Represented OpenInvest, a leading financial technology company that helps financial professionals customize and report on values-based investments, in its sale to J.P. Morgan.
LIVEKINDLY
Represented LIVEKINDLY Collective, a collection of heritage and start-up brands on track to become one of the world's largest plant-based food companies, on the commercial and intellectual property aspects of its establishment, together with RCL Foods, of a plant-based joint venture, LIVEKINDLY Collective Africa.
Adagene
Represent Adagene, a clinical stage biotech company, in a material transfer and research relationship associated with Adagene’s proprietary materials, with a major university.
Vizgen, Inc.
Represented Vizgen in a university licensing transaction to support Vizgen’s gene profiling instrumentation and data analysis, with a major university.
CareDx
Represented CareDx, a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, in licensing and research collaboration agreements with a major university, and in a material transfer agreement to support a feasibility study with CRISPR Therapeutics.
Colleges and Universities
Represented clients in licensing and other commercial life sciences transactions adverse to a number of universities including Harvard, MIT, Cornell, Stanford, University of California-San Diego, University of California-Berkeley, University of Pittsburgh, University of Michigan, Tufts, and Northeastern.
BluesphereBio
Represented BluesphereBio in all licensing matters, including pending deals with a major university and the university's medical center.
Rankings
Recognized as finalist for Intellectual Property Attorney of the Year
New England Legal Awards, 2024
Recommended for Media, Technology and Telecoms: Outsourcing
Legal 500 USA 2024
Band 1 in Massachusetts - Intellectual Property: Licensing
Chambers USA 2024
Recognized among the Best Lawyers for Information Technology Law
Best Lawyers in America 2024